Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyethylene glycol 3350 is a high-molecular-weight, water-soluble synthetic polymer derived from ethylene oxide. It is commonly used as an osmotic laxative to treat chronic constipation and for bowel cleansing prior to medical procedures. PEG 3350 is chemically and biologically inert, minimally absorbed by the gastrointestinal tract, and has high patient tolerability. Beyond therapeutic use, it serves as a pharmaceutical excipient, a component in cosmetics, a precipitant for protein and DNA isolation in molecular biology, and a crowding agent in biochemical research due to its ability to exert osmotic pressure and solubilize molecules. PEG 3350 is not considered a therapeutic target but rather an active pharmaceutical ingredient and versatile excipient.
Osmotic water retention in colon (prevents water reabsorption, increases osmotic pressure, softens stool, increases stool volume; thus stimulates peristalsis and facilitates defecation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyethylene glycol 3350 (PEG 3350).